Targeted therapies can reverse immune evasion programs in KRAS-mutant tumours, clearly operating through cell-autonomous and non-cell-autonomous mechanisms [2, 7], which can be enhanced by combination with ICB. The gene discussed is KRAS; the disease is neoplasm.